Navigation Links
Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp.
Date:4/14/2011

ALEXANDRIA, Va., April 14, 2011 /PRNewswire/ -- Oxford Finance Corporation (Oxford), a subsidiary of Sumitomo Corporation, today announced that it closed a $2 million equipment loan with Synta Pharmaceuticals Corp.  The funds will finance laboratory equipment used to manufacture compounds for use in Synta's ongoing clinical trials in the areas of oncology and chronic inflammatory diseases.

"Synta Pharmaceuticals has a diverse drug pipeline, including two leading cancer drugs currently in Phase 2 development in a broad range of indications," said Chad D. Norman, managing director for Oxford Finance.  "Oxford is very pleased to provide capital to support the development and delivery of Synta's novel pharmaceutical products."

About Oxford Finance Corporation

A subsidiary of Sumitomo Corporation, Oxford is a specialty finance firm providing senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1.5 billion in loans, with lines of credit ranging from $500 thousand to $40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Massachusetts and North Carolina. For more information visit www.oxfordfinance.com.

About Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.


'/>"/>
SOURCE Oxford Finance Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
2. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
3. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
4. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
5. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
6. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
7. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
8. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
9. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
10. Cumberland Pharmaceuticals Appoints Rick S. Greene as Vice President, Finance & Accounting
11. Huifeng Bio-Pharmaceutical Technology Announces New Senior Vice President of Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... FinancialBuzz.com News Commentary  ... According to new data published Arcview ... legal cannabis market is projected to continue to grow at ... the current presidential administration. The report created by Arcview,s data ... growth in this industry are the passage and subsequent implementation ...
(Date:3/24/2017)... A ReportsnReports.com report says, over the recent ... the global sales of Adcetris and Kadcyla have been witnessing rapid ... conjugates market is driven by large number of ADC drugs in ... offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major Company Profiles, spread ...
(Date:3/24/2017)... , March 24, 2017  GenomeDx Biosciences today announced ... Database) and Decipher® Prostate Cancer Classifier tests will be ... of Urology (EAU) Congress held March 24 to 28, ... Annual EAU Congress is Europe,s ... research in the urological field. The abstract ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... Viewers who like to educate themselves on current issues ... goods, services, and societal issues tend to appreciate and love the "Informed" series, hosted ... utilizing running events for causes around the world. , Running for charity ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding ... God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion with ... Walk with God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story ... fullest, as God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” ... passion for writing, especially about truth and human behavior. , Published by Christian Faith ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
(Date:3/23/2017)... ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the contributions of those whose ... significant impact on the careers of all others involved. , On Monday, March ... the MBI’s Hall of Fame. The induction took place during the World of Modular ...
Breaking Medicine News(10 mins):